<DOC>
	<DOCNO>NCT00002320</DOCNO>
	<brief_summary>To evaluate safety efficacy high-dose lamivudine ( 3TC ) alone versus zidovudine ( AZT ) alone versus 3TC high low dos combination AZT HIV-1 infect patient . PER 02/27/95 AMENDMENT : To evaluate efficacy safety blind open-label combination therapy .</brief_summary>
	<brief_title>A Comparison Lamivudine Zidovudine , Used Alone Together , HIV-Infected Patients Who Have Not Used Zidovudine Past</brief_title>
	<detailed_description>Patients randomize one four treatment arm : 3TC alone , AZT alone , low-dose 3TC plus AZT , high-dose 3TC plus AZT . Patients receive treatment 32 week , possible extension 52 week . PER 02/27/95 AMENDMENT : Patients may continue therapy AZT low-dose 3TC open-label basis . Open-label therapy continue follow-up every 8 week intolerable toxicity occur study terminates .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV positivity . CD4 count 200500 cells/mm3 . AZT naive status ( &lt; = 4 week prior AZT ) . Exclusion Criteria Patients follow prior condition exclude : History intolerance AZT . Prior Medication : Excluded : More 4 week prior AZT . Any prior antiretroviral treatment AZT .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1994</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>